GSK acquires global rights to China-developed multiple myeloma drug

GSK has expanded its pipeline by securing global rights to a multiple myeloma treatment developed in China, continuing its strategy of in-licensing assets from Chinese biotech firms. The deal underscores the growing cross-border flow of pharmaceutical innovation from China to Western markets. Financial terms and clinical stage are not disclosed, leaving the deal's materiality uncertain.